Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin.
作者信息
Aljaberi Rana, Wishah Kholoud
机构信息
Department of Pediatrics, Case Western Reserve University, MetroHealth Medical Centre, Cleveland, Ohio.
Department of Allergy Immunology, Case Western Reserve University, MetroHealth Medical Centre, Cleveland, Ohio.
出版信息
Ann Allergy Asthma Immunol. 2020 Sep;125(3):349-350. doi: 10.1016/j.anai.2020.06.006. Epub 2020 Jun 4.
Abstract
摘要
相似文献
1
Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin.
Ann Allergy Asthma Immunol. 2020 Sep;125(3):349-350. doi: 10.1016/j.anai.2020.06.006. Epub 2020 Jun 4.
2
The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019.
Ann Allergy Asthma Immunol. 2020 Jul;125(1):112-114. doi: 10.1016/j.anai.2020.04.033. Epub 2020 May 5.
3
Ten things we learned about COVID-19.
Intensive Care Med. 2020 Aug;46(8):1590-1593. doi: 10.1007/s00134-020-06140-0. Epub 2020 Jun 5.
4
Clinical findings in a patient with haemophilia A affected by COVID-19.
Haemophilia. 2020 Jul;26(4):e214-e216. doi: 10.1111/hae.14000. Epub 2020 Apr 13.
5
A COVID-19 case in Libya acquired in Saudi Arabia.
Travel Med Infect Dis. 2020 Sep-Oct;37:101705. doi: 10.1016/j.tmaid.2020.101705. Epub 2020 May 1.
6
SARS-CoV-2 in upper and lower airway samples of a laryngectomized patient: New insights and many lessons.
Oral Oncol. 2020 Aug;107:104841. doi: 10.1016/j.oraloncology.2020.104841. Epub 2020 Jun 4.
7
[COVID-19- what have we learned and where are we heading?].
Laeknabladid. 2020 Oct;106(10):449. doi: 10.17992/lbl.2020.10.598.
8
Dysregulated adaptive immune response contributes to severe COVID-19.
Cell Res. 2020 Sep;30(9):814-816. doi: 10.1038/s41422-020-0391-9. Epub 2020 Aug 5.
9
Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.
Indian Pediatr. 2020 Jul 15;57(7):681-683. doi: 10.1007/s13312-020-1901-z. Epub 2020 May 10.
10
Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.
Autoimmun Rev. 2020 Jun;19(6):102538. doi: 10.1016/j.autrev.2020.102538. Epub 2020 Apr 5.
引用本文的文献
1
Monitoring of immunoglobulin treatment compliance of patients with an inborn error of immunity during the pandemic period.
BMC Immunol. 2025 Mar 15;26(1):22. doi: 10.1186/s12865-025-00703-w.
2
Tolerability and outcomes with rollout of tixagevimab-cilgavimab in patients with common variable immunodeficiency.
J Allergy Clin Immunol Glob. 2024 Jun 13;3(3):100293. doi: 10.1016/j.jacig.2024.100293. eCollection 2024 Aug.
3
Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines.
Tuberk Toraks. 2023 Sep;71(3):236-249. doi: 10.5578/tt.20239705.
4
Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity.
J Allergy Clin Immunol. 2023 Apr;151(4):818-831. doi: 10.1016/j.jaci.2022.11.010. Epub 2022 Dec 13.
5
COMMON VARIABLE IMMUNODEFICIENCY: PREDISPOSING OR PROTECTIVE FACTOR FOR SEVERE COMPLICATIONS OF COVID-19?
Acta Clin Croat. 2022 Mar;61(1):107-114. doi: 10.20471/acc.2022.61.01.13.
6
COVID-19 and Inborn Errors of Immunity.
Physiology (Bethesda). 2022 Nov 1;37(6):0. doi: 10.1152/physiol.00016.2022. Epub 2022 Aug 9.
7
COVID-19 Infection in Patients with Humoral Immunodeficiency: A Case Series and Literature Review.
Allergy Rhinol (Providence). 2022 Apr 25;13:21526575221096044. doi: 10.1177/21526575221096044. eCollection 2022 Jan-Dec.
8
Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency.
J Allergy Clin Immunol Pract. 2022 Feb;10(2):633-636.e3. doi: 10.1016/j.jaip.2021.11.030. Epub 2021 Dec 18.
9
B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
Cells. 2021 Oct 27;10(11):2915. doi: 10.3390/cells10112915.
10
Potential therapeutic approach of intravenous immunoglobulin against COVID-19.
Allergy Asthma Clin Immunol. 2021 Oct 9;17(1):105. doi: 10.1186/s13223-021-00609-3.
本文引用的文献
1
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102. doi: 10.1093/ofid/ofaa102. eCollection 2020 Mar.
2
SARS-CoV-2: a storm is raging.
J Clin Invest. 2020 May 1;130(5):2202-2205. doi: 10.1172/JCI137647.
3
COVID-19: the new challenge for rheumatologists.
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):175-180. doi: 10.55563/clinexprheumatol/r3k9l6. Epub 2020 Mar 24.
4
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
7
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
8
Immunomodulation by IVIg and the Role of Fc-Gamma Receptors: Classic Mechanisms of Action after all?
Front Immunol. 2015 Jan 21;5:674. doi: 10.3389/fimmu.2014.00674. eCollection 2014.
Zotero 插件